Kobayashi in ¥500 billion buyout talks after red-yeast case
CVC Capital Partners and Nippon Sangyo Suishin Kiko are weighing a bid to take the company private, sources said.
Japanese health products firm Kobayashi Pharmaceutical is reportedly in talks for a potential buyout of over ¥500 billion ($3.2 billion) by private equity firms CVC Capital Partners and Nippon Sangyo Suishin Kiko, according to sources familiar with the negotiations. The proposal, which has not been confirmed by Kobayashi, could also see the company's founding family involved in the acquisition.
The talks emerged following a recent supplement contamination scandal that has raised concerns about potential deaths. As of now, no decisions have been finalized. Kobayashi's shares were not trading at the Tokyo market opening and were expected to rise.
Written by urgent.news from Japan Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
